Lucid Diagnostics (LUCD) Earnings Date & Reports

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

LUCD is expected to report earnings to fall 16.25% to -13 cents per share on August 18

Lucid Diagnostics LUCD Stock Earnings Reports

Q2'25

Est.

$-0.13

Q1'25

Beat

by $0.03

Q4'24

Missed

by $0.02

Q3'24

Beat

by $0.01

Q2'24

Est.

$-0.20

The last earnings report on May 14 showed earnings per share of -15 cents, beating the estimate of -18 cents. With 959.47K shares outstanding, the current market capitalization sits at 42.94M.

View a ticker or compare two or three

Compare

LUCD